Company Overview

ImmuCell Corporation is a U.S.-based animal health company focused on the development, manufacturing, and sale of products that improve the health, productivity, and profitability of dairy and beef cattle. The company operates within the animal health, veterinary pharmaceuticals, and agricultural biotechnology industries. Its core business centers on biologic products, particularly antibody-based solutions, that help prevent disease and enhance herd performance in commercial cattle operations.

ImmuCell’s primary revenue drivers are mastitis prevention products for dairy cows and nutritional supplements designed to improve calf health and immune function. The company primarily serves dairy producers, veterinarians, and animal health distributors in the United States. Its strategic advantage lies in its proprietary antibody technologies and specialized focus on immunology-based solutions for cattle, a niche that differentiates it from larger diversified animal health companies. Founded in 1987, ImmuCell has evolved from a research-oriented biotechnology firm into a commercial-stage animal health company with FDA-approved products and an expanding development pipeline.

Business Operations

ImmuCell generates revenue through the manufacture and sale of biologic animal health products, with operations organized around its core product lines rather than formally disclosed operating segments. Its flagship product, First Defense®, is an FDA-licensed oral antibody product used to protect newborn calves against enteric pathogens, representing the company’s largest source of revenue. The company also markets California Mastitis Test (CMT®) reagents, which are used to detect subclinical mastitis in dairy cows and provide a steady, recurring revenue stream.

Operations are primarily domestic, with manufacturing, research, and administrative functions located in the United States, particularly in Maine. ImmuCell controls proprietary antibody production processes and maintains in-house manufacturing capabilities for its biologics. The company distributes products through animal health distributors and direct sales channels. As of public disclosures, ImmuCell does not report material joint ventures but operates through wholly owned subsidiaries supporting production and commercialization activities.

Strategic Position & Investments

ImmuCell’s strategic direction emphasizes expanding its product portfolio through internal research and regulatory advancement of new biologic therapies. A key growth initiative is the development of Mast Out®, a novel intramammary treatment for mastitis intended to reduce or replace traditional antibiotics, addressing increasing regulatory and consumer pressure to limit antibiotic use in food-producing animals. The company has made sustained investments in clinical trials, regulatory submissions, and manufacturing scale-up related to this product.

The company’s investment strategy is conservative and internally focused, prioritizing organic growth rather than large-scale acquisitions. Capital expenditures have been directed toward manufacturing infrastructure, quality systems, and research and development capabilities. ImmuCell’s involvement in emerging sectors is concentrated on antibiotic alternatives, immunotherapy, and biologic disease prevention within animal agriculture, aligning with broader industry trends toward sustainability and responsible antibiotic use.

Geographic Footprint

ImmuCell’s operations are primarily concentrated in North America, with its headquarters and principal facilities located in Maine, United States. The company’s products are sold predominantly in the U.S. dairy and beef markets, which account for the majority of its revenue and operational focus.

While ImmuCell has limited direct international operations, its products have some exposure to international markets through distributors and regulatory approvals in select countries. However, based on available public disclosures, international sales represent a relatively small portion of total revenue, and the company’s strategic emphasis remains on expanding penetration within the U.S. cattle industry.

Leadership & Governance

ImmuCell is led by an executive team with long-standing experience in animal health, biotechnology, and regulatory-driven industries. The company’s leadership philosophy emphasizes scientific rigor, regulatory compliance, and disciplined capital allocation to support long-term value creation rather than rapid expansion.

Key executives include:

• Michael F. Brigham – President and Chief Executive Officer
• Walter G. Van Lehmden – Chief Financial Officer
• Gerald L. Heffernan – Vice President of Manufacturing
• David E. Anderson – Vice President of Research and Development

The company is publicly traded and governed by a board of directors responsible for oversight of strategy, risk management, and regulatory compliance, with governance practices aligned with U.S. public company standards and SEC filings.